We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.925 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
TIDMAVO
RNS Number : 7433H
Advanced Oncotherapy PLC
12 June 2017
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Technological milestones update
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces further notable progress in the manufacture of its first LIGHT system.
Patient Positioning System
Multiple components of the treatment room have been manufactured, inspected and tested by the Company's partner P-Cure Ltd. ("P-Cure"), ahead of their integration to form a complete patient treatment system.
The patient positioning subsystem, which includes the patient treatment chair and robotic arm which moves the chair and patient, is complete and has been designed to leverage LIGHT's next-generation features. As other subsystems are completed, such as imaging and treatment management software, they will be integrated to form the whole Patient Positioning System, which remains on track to be fully developed by the end of 2017.
Beam firing through RFQ
As indicated in the Investor presentation and update of 6 March 2017, the proton beam was fired through the Radio Frequency Quadrupole ("RFQ"), at its maximum expected energy, in February 2017. Subsequent work has focused on enhancing the proton source that feeds the RFQ; repeatability of beam firing, intensive usage to facilitate high patient throughput and maximising safety controls are all key elements of LIGHT.
Ionisation chamber
In addition, the Company announces it has received delivery of the LIGHT system's ionisation chamber, from its partner Pyramid Technical Consultants Inc., to its Geneva testing facility. The ionisation chamber is a critical element of the LIGHT system's overall safety system, monitoring beam position, spot size and dosage and is situated at the delivery end of the system after the main accelerating modules.
The novel design of the chamber is matched to the unique properties of LIGHT and performs a precise measurement of the position (in horizontal and vertical axes) of the proton beam, with respect to its desired location, and is a critical element of the LIGHT system's Patient Treatment System. It also accurately monitors the dose (number of protons) delivered to the target. The properties of the LIGHT ionisation chamber allow these measurements to be taken, on a pulse by pulse basis, ensuring accuracy and safety throughout treatment, to a level that cannot be matched by older proton therapy technologies.
Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy, said: "As I outlined in my update to shareholders in March, the Company remains focused on delivering the technical development of our first LIGHT machine and its ultimate installation at Harley Street, and I am very pleased with the progress we are making.
"We will continue to update the market with newsflow on the integration of the LIGHT system's components, with developments on the CCL units, addition of the SCDTLs to the RFQ and on the Patient Positioning System anticipated in the coming weeks and months."
Advanced Oncotherapy Plc www.avoplc.com Dr. Michael Sinclair, Tel: +44 20 3617 8728 Executive Chairman Nicolas Serandour, CEO Stockdale Securities (Nomad & Joint Broker) Antonio Bossi / David Tel: +44 20 7601 6100 Coaten Stifel Nicolaus Europe (Joint Broker) Jonathan Senior / Ben Tel: +44 20 7710 7600 Maddison Walbrook PR (Financial Tel: +44 20 7933 8780 or PR & IR) avo@walbrookpr.com Paul McManus / Anna Dunphy Mob: +44 7980 541 893 / Mob: +44 7876 741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUAAARBKANAUR
(END) Dow Jones Newswires
June 12, 2017 02:00 ET (06:00 GMT)
1 Year Advanced Oncotherapy Chart |
1 Month Advanced Oncotherapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions